COMMUNIQUÉS West-GlobeNewswire

Health Catalyst to Announce Second Quarter 2019 Operating Results and Host Conference Call on Thursday, August 22, 2019
08/08/2019
SALT LAKE CITY, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced [...]
Agritek Holdings Inc. to Acquire Apex Solutions, a Licensed Manufacturer, Producer and Distributor of Award-Winning Cannabis Products in California
08/08/2019
LOS ANGELES, Aug. 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Agritek Holdings Inc. (OTC: AGTK), a fully integrated investor in the legal cannabis sector, today announced that it has entered into a binding letter [...]
Sol-Gel Announces Pricing of Public Offering of Ordinary Shares
08/08/2019
NESS ZIONA, Israel, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing [...]
Geron Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
08/08/2019
MENLO PARK, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate imetelstat, a first-in [...]
Protech Home Medical Announces Date and Time for Quarterly Conference Call
08/08/2019
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. CINCINNATI, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Protech Home [...]
Chimerix Announces Second Quarter 2019 Financial Results and Operational Update
08/08/2019
Pipeline Transformed with Acquisition of Global Rights to Late Stage Oncology Asset (CX-01) with Fast Track and Orphan Drug Designation Phase 3 Trial of CX-01 in Front-Line Acute Myeloid Leukemia Planned to Initiate in [...]
Spectral Medical Provides Corporate Update
08/08/2019
TORONTO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ( “Spectral” or the “Company” ) (TSX: EDT) , a Phase III company developing the first treatment for patients with septic shock guided by a companion [...]
TYME Provides Business Update and Reports First Quarter Fiscal 2020 Financial and Operating Results
08/08/2019
TYME Presented Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer NYU Langone and TYME Entered into a Research [...]
Catalyst Biosciences to Host Key Opinion Leader Meeting on Next-Generation Subcutaneous Factor VIIa Marzeptacog Alfa (Activated) in Patients with Bleeding Disorders on August 15
08/08/2019
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that it will host a Key Opinion Leader (KOL) meeting on next-generation subcutaneous Factor VIIa [...]
Aravive Announces Participation at Wedbush PacGrow Healthcare Conference
08/08/2019
HOUSTON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, today announced [...]
Dynavax Technologies Announces Pricing of $70.1 Million Public Offering of Common Stock, Non Voting Preferred Stock and Warrants to Purchase Common Stock
08/08/2019
EMERYVILLE, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a fully-integrated biopharmaceutical company focused on discovering, developing and commercializing novel vaccines, [...]
Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
08/08/2019
- New strategic partnership with gene therapy leader, AskBio, to jointly develop next-generation AAV-based gene therapies to address the unmet medical need for repeat dosing in patients with rare and orphan genetic [...]
Progenics Pharmaceuticals Announces Additional Governance Enhancements
08/08/2019
Board Accepts Resignations of Directors Peter J. Crowley and Michael D. Kishbauch, Effective October 17, 2019 Board Names New Committee Chairs Board Adopts Stock Ownership Guidelines for Directors and Officers Members [...]
Ziopharm Oncology Reports Second Quarter 2019 Financial Results
08/08/2019
– FDA Cleared IND for Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors at the National Cancer Institute (NCI) – – Exclusive license from NCI for library of T-cell receptors (TCRs) [...]
Autolus Therapeutics Reports Second Quarter 2019 Financial Results and Operational Progress
08/08/2019
Conference call to be held on August 8, 2019 at 8:30 am EDT/1:30 pm BST LONDON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next- [...]
Ziopharm Oncology Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Glioma
08/08/2019
BOSTON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted [...]
Albireo Reports Second Quarter 2019 Financial Results
08/08/2019
— Odevixibat Phase 3 PEDFIC 1 topline results expected mid-2020 — — Initiated elobixibat Phase 2 trial in NAFLD/NASH — — Management to host conference call and webcast today at 10 a.m. EDT — BOSTON, Aug. 08, 2019 (GLOBE [...]
Atara Biotherapeutics Announces Second Quarter 2019 Financial Results and Recent Operational Progress
08/08/2019
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
Achillion Reports Second Quarter 2019 Financial Results and Provides Corporate Update
08/08/2019
– Danicopan (ACH-4471) Phase 2 combination therapy interim data showed clinically meaningful improvements in laboratory parameters of PNH; End-of-Phase 2 meeting activities initiated with FDA – – ACH-5228’s near [...]

Pages